- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01618968
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
May 8, 2014 updated by: Antares Pharma Inc.
Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis
Relative Bioavailability Comparison study
Study Overview
Detailed Description
A Phase 2, Open-Label, Randomized, 3-Way Crossover Study to Compare the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis
Exclusion Criteria:
- Pregnant females
- Any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10 mg Methotrexate (MTX)
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status.
The sequence of treatments A, B and C was randomly assigned.
|
Other Names:
|
Experimental: 15 mg MTX
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status.
The sequence of treatments A, B and C was randomly assigned.
|
Other Names:
|
Experimental: 20 mg MTX
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status.
The sequence of treatments A, B and C was randomly assigned.
|
Other Names:
|
Experimental: 25 mg MTX
MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status.
The sequence of treatments A, B and C was randomly assigned.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Normalized AUC[0-Inf] for MTX
Time Frame: 24 Hour period
|
Dose-normalized area under the curve from time zero to infinity (AUC[0-inf]/Dose) for each treatment
|
24 Hour period
|
Dose-Normalized AUC[0-24] for MTX
Time Frame: 24 Hour period
|
Dose-normalized area under the curve from time zero to 24 hours (AUC[0-24]/Dose) for each treatment
|
24 Hour period
|
Dose-Normalized Cmax for MTX
Time Frame: 24 Hour period
|
Dose-normalized maximum observed concentration (Cmax) for each treatment
|
24 Hour period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alan J Kivitz, MD;CPI, Altoona Center for Clinical Research
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
June 4, 2012
First Submitted That Met QC Criteria
June 12, 2012
First Posted (Estimate)
June 14, 2012
Study Record Updates
Last Update Posted (Estimate)
May 19, 2014
Last Update Submitted That Met QC Criteria
May 8, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MTX-11-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis (RA)
-
SinoMab BioScience LtdRecruitingRheumatoid Arthritis(RA)China
-
Veena Ranganath, MD, MSRecruiting
-
AbbVieActive, not recruitingRheumatoid Arthritis (RA)Argentina, Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Kuwait, Mexico, Russian Federation, Saudi Arabia, Spain, Switzerland, Taiwan, United Arab Emirates, Uruguay
-
Astellas Pharma China, Inc.CompletedRheumatoid Arthritis (RA)China, Korea, Republic of, Taiwan
-
Jiangsu HengRui Medicine Co., Ltd.CompletedRheumatoid Arthritis (RA)China
-
Faiq GorialCompleted
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Bristol-Myers SquibbUnknown
-
medac GmbHPPDCompletedRheumatoid Arthritis (RA)United States
-
Antares Pharma Inc.CompletedRheumatoid Arthritis (RA)United States
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
Clinical Trials on MTX
-
Chugai PharmaceuticalCompletedRheumatoid Arthritis
-
Grünenthal GmbHCompletedOsteoarthritis, KneeBelgium
-
Mozart Therapeutics Australia Pty LtdNot yet recruitingType 1 Diabetes | Celiac Disease | Healthy VolunteersAustralia
-
Alimentiv Inc.AbbottTerminated
-
Hoffmann-La RocheCompletedJuvenile Idiopathic ArthritisChina
-
Zhejiang Hisun Pharmaceutical Co. Ltd.CompletedModerate to Severe Active Rheumatoid ArthritisChina
-
The Children's Hospital of Zhejiang University...CompletedMethotrexate Adverse ReactionChina
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Memo Therapeutics AGCompletedSARS-CoV-2 InfectionAustralia
-
Ding MaShandong University; Huazhong University of Science and Technology; Zhejiang...UnknownGestational Trophoblastic Tumor | Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Disease | Gestational Trophoblastic NeoplasmsChina